EDMONTON, Alberta — September 12, 2013. Fedora Pharmaceuticals, Inc. and its collaborators presented results of preclinical studies demonstrating that FPI-1465 increases the activity of β-lactam antibiotics against bacteria that have developed resistance through the production of β-lactamase enzymes.
In vitro, three β-lactam antibiotics (ceftazidime, aztreonam, and meropenem) were tested alone and in combination with FPI-1465. In each case the combination eliminated resistant bacteria at much lower concentrations. Against carbapenemase-producing bacteria, aztreonam showed up to 4,096-fold greater potency in combination with FPI-1465.
The synergy observed in these studies suggests that FPI-1465 has the potential to negate the mechanism of resistance employed by β-lactamase-producing bacteria and rescue the antimicrobial activity of the entire class of β-lactam antibiotics.Dr. Rodrigo E. Mendes, Associate Director, JMI Laboratories
Results were confirmed in vivo: in mice infected with resistant Klebsiella pneumoniae or Enterobacter cloacae, a single dose of FPI-1465 plus ceftazidime produced a roughly 3-log reduction in bacterial counts.
In these highly resistant strains, the degree of bacterial clearance generated by the combination of FPI-1465 plus ceftazidime is truly impressive.Christopher G. Micetich, Founder & CEO, Fedora Pharmaceuticals
About Fedora Pharmaceuticals
Fedora Pharmaceuticals Inc. is an innovative biotech founded in 2011 and headquartered in Edmonton, Alberta, Canada. The company is dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance (AMR). Fedora’s most advanced candidate is nacubactam, a Phase 3-ready β-lactamase inhibitor being advanced with partner Meiji Seika; Fedora holds key US rights to nacubactam. For more information, visit fedorapharma.com.
